Published in Genetics and Environmental Law Weekly, January 14th, 2006
At the 47th Annual Meeting of the American Society of Hematology (ASH), the investigators reported marked improvement in outcome in all three phases of chronic myeloid leukemia (CML) as well as benefit in treating a form of acute lymphocytic leukemia (ALL) that shares the same genetic abnormality as CML, the Philadelphia chromosome.
"This drug is very promising and appears at this point to offer an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.